Natera, Inc. - Common Stock (NTRA)
310.67
-53.09 (-14.59%)
NASDAQ · Last Trade: Nov 7th, 3:13 PM EST
News & Press Releases
Natera (NTRA) Q3 2026 Earnings Call Transcriptfool.com
Natera's new CEO outlines a path to double revenue by 2029
Via The Motley Fool · November 6, 2026
What Natera (NTRA) Said on Its Q3 Earnings Callmarketbeat.com
Natera (NASDAQ:NTRA) raised its full-year revenue forecast after reporting a 34% increase in third-quarter revenue, as demand for its cancer-monitoring tests grew and the company announced a change in leadership.
Steve Chapman is stepping down as chief executive officer and handing the role to Solo
Via MarketBeat · November 6, 2026
NTRA Q3 2026 deep dive: management transition and pharma business investments offset margin gains
Genetic testing company Natera (NASDAQ:NTRA) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 34.1% year on year to $794 mi...
Via StockStory · November 6, 2026
Natera (NASDAQ:NTRA) Q3 Revenue Beat Overshadowed by Profitability Miss and Selloffchartmill.com
Via Chartmill · November 5, 2026
Natera (NASDAQ:NTRA) delivers impressive Q3 2026 but stock drops 19.7%
Genetic testing company Natera (NASDAQ:NTRA) reported Q3 2026 results exceeding the market’s revenue expectations, with revenue up 34.1% year on year to $794...
Via StockStory · November 5, 2026
After-Hours Market Movers for Nov. 5, 2026: Gainers and Loserschartmill.com
Via Chartmill · November 5, 2026
Natera Announces Leadership Transition
Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, today announced that Solomon Moshkevich has been appointed Chief Executive Officer and a member of the Board of Directors, effective immediately.
By Natera, Inc. · Via Business Wire · November 5, 2026
Natera Reports Third Quarter 2026 Financial Results
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the third quarter ended September 30, 2026.
By Natera, Inc. · Via Business Wire · November 5, 2026
Signatera™ Monitoring During First-Line Immunotherapy Showed ctDNA Clearance is Associated with Long-Term Survival Across Four Metastatic Cancers
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced it will present important new Signatera data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place November 4–8 in Phoenix, Arizona.
By Natera, Inc. · Via Business Wire · November 5, 2026
Signatera™ in Head and Neck Cancer: Three New Publications Demonstrate Strong Clinical Performance and Actionability
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced three peer-reviewed publications in npj Precision Oncology, JAMA Otolaryngology, and Advances in Radiation Oncology, highlighting the performance of its Signatera test in head and neck squamous cell carcinoma (HNSCC).
By Natera, Inc. · Via Business Wire · November 4, 2026
Natera (NTRA) to report earnings tomorrow: here is what to expect
Genetic testing company Natera (NASDAQ:NTRA) will be announcing earnings results this Thursday after the bell. Here’s what to expect. Natera beat analysts’ r...
Via StockStory · November 3, 2026
Medicare Expands Coverage for Signatera™ MRD Test in Hepatocellular Carcinoma
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its Signatera molecular residual disease (MRD) test has received Medicare coverage through the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostics Services Program (MolDX) in hepatocellular carcinoma (HCC). The coverage includes serial Signatera testing in the surveillance setting for patients with early-stage HCC who have no post-surgical evidence of disease.
By Natera, Inc. · Via Business Wire · November 3, 2026
Natera to Report its Third Quarter Results on November 5, 2026
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its third quarter ended September 30, 2026, after the market closes on November 5, 2026. Natera will host a conference call and webcast shortly thereafter at 4:30 p.m. ET.
By Natera, Inc. · Via Business Wire · October 29, 2026
Signatera™ Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today provided a summary of key findings from the European Society for Medical Oncology (ESMO) Congress 2026. Following the presentation of several late-breaking datasets over the weekend, Natera’s technology was included in 25 abstracts, including 9 oral presentations, along with two concurrent publications.
By Natera, Inc. · Via Business Wire · October 27, 2026
Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight™
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data that was recently presented at the American Society of Nephrology (ASN) Kidney Week 2026, highlighting the unique value genetic testing can provide for patients with CKD. These 18 abstracts, including three oral presentations, add to the growing support for Renasight, Natera’s genetic test for CKD.
By Natera, Inc. · Via Business Wire · October 26, 2026
Stanley Druckenmiller Has Bet Big on This 1 Healthcare Stock. Here's Why I Disagree.fool.com
The business is promising, but the valuation today has gone to the stratosphere.
Via The Motley Fool · October 25, 2026
Why Natera (NTRA) Stock Is Up Today
What Happened? Shares of genetic testing company Natera (NASDAQ:NTRA) jumped 2.4% in the afternoon session after the company announced that incorporating pha...
Via StockStory · October 19, 2026
ESMO 2026 Presentations Deepen the Evidence Base for Natera’s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts featuring its technology will be presented at the 2026 European Society for Medical Oncology (ESMO) Annual Congress, taking place October 23–26 in Madrid, Spain.
By Natera, Inc. · Via Business Wire · October 18, 2026
Natera’s Signatera™ MRD Test Named to TIME’s List of the Best Inventions of 2026
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its Signatera molecular residual disease (MRD) test has been named to TIME’s Best Inventions of 2026 list, featuring extraordinary innovations that are changing lives.
By Natera, Inc. · Via Business Wire · October 15, 2026
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and TransCode Therapeutics, Inc. (Nasdaq: RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based therapeutics for the treatment of high-risk and advanced cancers, today announced a strategic collaboration in colorectal cancer (CRC).
By Natera, Inc. · Via Business Wire · October 13, 2026
Why Natera (NTRA) Stock Is Up Today
What Happened? Shares of genetic testing company Natera (NASDAQ:NTRA) jumped 1.7% in the morning session after the U.S. Food and Drug Administration granted ...
Via StockStory · October 9, 2026
FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its multi-cancer early detection (MCED) assay has been granted Breakthrough Device designation (BDD) by the U.S. Food and Drug Administration (FDA). The BDD is designed for novel technologies that enable more effective diagnosis or treatment of life-threatening or irreversibly debilitating diseases or conditions.
By Natera, Inc. · Via Business Wire · October 9, 2026
3 Market-Beating Stocks with Competitive Advantages
Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that ca...
Via StockStory · October 8, 2026
Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the enrollment of the first patients in a new Signatera-guided trial in melanoma (NCT07504796), sponsored by NYU Langone Health.
By Natera, Inc. · Via Business Wire · October 7, 2026
New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data recently shared at the American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting. The presentations marked Natera’s first participation at ASTRO and a significant step in demonstrating Signatera’s role in treatment response monitoring and risk stratification. All four abstracts were selected for oral presentations, reflecting the breadth of tumor types and treatment settings in which Signatera is demonstrating clinical utility.
By Natera, Inc. · Via Business Wire · October 6, 2026